CYBERSPACE – At a series of new drugs on the horizon sessions at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting I, a variety of companies presented preclinical and clinical data for promising early stage oncology products.
DUBLIN – Thrive Earlier Detection Corp. and its academic and clinical collaborators have provided a first glimpse at the utility of a liquid biopsy test as a screening tool for picking up cancers in an asymptomatic population. In an interim one-year readout of data from the prospective five-year DETECT-A study in 10,000 women, an early version of Thrive’s Cancerseek test picked up 26 cancers ahead of standard-of-care screening, while the latter modality picked up another 24 cancers that Cancerseek missed.
New and updated preclinical and clinical data presented by biopharma firms at the American Association for Cancer Research’s Virtual Annual Meeting, including: Karus, Noxxon, Oric, Syndax, Tarveda, Trovagene.
New and updated preclinical and clinical data presented by biopharma firms at the American Association for Cancer Research’s Virtual Annual Meeting, including: Alligator, Alpine Immune, Aptose, Astrazeneca, Compugen, Iteos, Macrogenics, Merck, Rgenix, Ribon, Sutro, Theratechnologies, Vaccinex, Verastem.
SAN DIEGO – Allele-specific KRAS inhibitors are “the most exciting change coming down the pike for treating KRAS-mutant tumors in the near future,” Ferdinandos Skoulidis said at the sixth joint conference by the American Association for Cancer Research and the International Association for the Study of Lung Cancer meeting.
RSS
